Modified AutoSet Device vs Existing AutoSet Device, the Assessment of Efficacy and Subjective Comfort of the Treatment.

NCT ID: NCT00906958

Last Updated: 2021-03-22

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

20 participants

Study Classification

INTERVENTIONAL

Study Start Date

2009-05-11

Study Completion Date

2009-06-15

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to determine if the performance of the modified AutoSet device is equivalent or better than the existing AutoSet device (VPAP Auto) in the efficacy of the treatment and the subjective comfort.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Obstructive sleep apnea (OSA) is characterised by a partial or complete collapse of the upper airway during sleep. The treatment of choice for OSA is Continuous Positive Airway Pressure (CPAP). CPAP acts as a positive airway splint, delivering a fixed or auto adjusted positive pressure to the upper airway via a tube and mask. The modified device to be assessed in this study will act in a similar way to the existing device, VPAP Auto, but utilizes an improved algorithm which should maintain or enhance the effectiveness of the treatment.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Sleep Apnea

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

CROSSOVER

Primary Study Purpose

TREATMENT

Blinding Strategy

SINGLE

Participants

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Nexus Flow Generator

Participants were randomised to Nexus Flow Generator group for one night.

Group Type EXPERIMENTAL

Nexus Flow Generator

Intervention Type DEVICE

The modified device to be assessed in this study will act in a similar way to the existing device, VPAP Auto, but utilises an improved algorithm which should maintain or enhance the effectiveness of the treatment.

VPAP Flow Generator 25

Participants were randomised to VPAP Flow Generator 25 group for one night.

Group Type ACTIVE_COMPARATOR

VPAP Flow Generator 25

Intervention Type DEVICE

Exiting VPAP Auto 25 Flow Generator with A10 Algorithm

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Nexus Flow Generator

The modified device to be assessed in this study will act in a similar way to the existing device, VPAP Auto, but utilises an improved algorithm which should maintain or enhance the effectiveness of the treatment.

Intervention Type DEVICE

VPAP Flow Generator 25

Exiting VPAP Auto 25 Flow Generator with A10 Algorithm

Intervention Type DEVICE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Patients aged 18-80 years
* Patients who are on CPAP therapy in AUTOSET mode for no less than 6 months
* Patients who are using ResMed masks

Exclusion Criteria

* Patients who are unable to provide written informed consent
* Patients who are unable to comprehend written and spoken English
* Patients who are using Bilevel PAP
* Patients who are pregnant
* Patients who are suffering any of the following:

* Acute respiratory infection
* Acute sinusitis, otitis media or perforated eardrum
* Pneumothorax or pneumomediastinum
* Recent history of severe epistaxis requiring medical attention
Minimum Eligible Age

18 Years

Maximum Eligible Age

80 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

ResMed

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Klaus Schindhelm, PhD

Role: PRINCIPAL_INVESTIGATOR

ResMed/The University of New South Wales

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Centre for Healthy Sleep

Bella Vista, New South Wales, Australia

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Australia

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

08177-0608

Identifier Type: -

Identifier Source: org_study_id

NCT00773396

Identifier Type: -

Identifier Source: nct_alias

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

CPAP Device In-lab Assessment NZ
NCT02948010 COMPLETED NA
Nexus Compliance Study
NCT01013207 COMPLETED NA
SensAwake™ Sleep Quality Trial
NCT00811213 COMPLETED PHASE4